This study will provide evidence on the characteristics of patients treated with isatuximab, when approved, in the RW setting, likely as part of combination therapy (with pomalidomide and dexamethasone or with carfilzomib and dexamethasone) and will shed light on treatment strategies utilized in daily clinical practice and their effectiveness and safety outcomes; the impact of which on patients’ QoL will be an important factor in interpreting differences in prognosis and outcomes in varying patient groups with RRMM.
21st Century Oncology will be moving to their new home as part of the global GenesisCare network. The 21st Century Oncology website will no longer exist after November 2020.
There will be no disruption in your care team, location, or contacts. There will simply be a new website, new look and feel, and patients will benefit from the latest treatment technology and evidence-based cancer care. We look forward to serving you as part of the GenesisCare team.